Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
The current price of SVRA is $5.56 USD — it has decreased by -0.36% in the past 24 hours. Watch Savara stock price performance more closely on the chart.
What is Savara stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Savara stocks are traded under the ticker SVRA.
Is Savara stock price growing?▼
SVRA stock has risen by +8.17% compared to the previous week, the month change is a +1.28% rise, over the last year Savara has showed a +95.09% increase.
What is Savara market cap?▼
Today Savara has the market capitalization of 1.13B
When is the next Savara earnings date?▼
Savara is going to release the next earnings report on May 07, 2026.
What were Savara earnings last quarter?▼
SVRA earnings for the last quarter are -0.13 USD per share, whereas the estimation was -0.12 USD resulting in a -9.47% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Savara revenue for the last year?▼
Savara revenue for the last year amounts to 0 USD.
What is Savara net income for the last year?▼
SVRA net income for the last year is -191.76M USD.
How many employees does Savara have?▼
As of April 05, 2026, the company has 59 employees.
In which sector is Savara located?▼
Savara operates in the Health Care sector.
When did Savara complete a stock split?▼
The last stock split for Savara was on April 28, 2017 with a ratio of 1:70.